
A new study by researchers in China has found that non-invasive prenatal testing (NIPT) detects twice as many cases of Down syndrome (DS) as second-trimester serum screening (STSS), while also being more cost-effectiveness. The study, published in the journal Frontiers in Public Health, was a retrospective analysis of clinical data from more than 140,000 pregnant women who underwent both NIPT and STSS testing to analyze the sensitivity, specificity, and positive predictive value (PPV) of the two screening methods.
“This study proves that NIPT has superior testing performance compared to STSS, signaling a significant step toward better prenatal care,” the study authors noted in a press release. “It provides clear evidence that NIPT not only enhances the accuracy of Down syndrome screening but also offers substantial cost savings, making it a feasible option for widespread adoption.”
The study was conducted by researchers from Changsha Hospital for Maternal & Child Health Care, the School of Public Administration at Hunan University, and BGI Genomics. It showed that NIPT exhibited significantly higher sensitivity, specificity, and PPV across all ages groups compared with STSS for the detection of Down syndrome, also known as trisomy 21.
This performance also led to lower overall healthcare costs. The universal NIPT screening strategy, which offers the test to all pregnant women, identified 163 cases of DS, with a cost-effectiveness ratio of RMB (the currency of China) 1:9.53. In contrast, a combined STSS and NIPT strategy detected fewer cases at a higher cost. This finding supports NIPT as both a clinically effective and economically viable option when implemented broadly. The researchers also noted that NIPT reduced the need for invasive prenatal diagnostic procedures, thereby minimizing associated medical risks and optimizing healthcare resources.
The study builds on prior research from Europe and China that has shown better performance of NIPT over serum-based methods. These earlier studies, however, were often limited by their small sample sizes or modeled simulations. The current research used a real-world dataset through the Changsha municipal public welfare program, which lowered the cost of NIPT to RMB 600 (about $85), enabling more robust cost-effectiveness modeling.
“This study analyzed outcomes from a healthcare system perspective, including medical costs in the calculations, allowing for a more comprehensive comparison of the health economic outcomes of different strategies within real-world healthcare settings,” the researchers wrote.
While the findings support the implementation of NIPT as a first-tier screening strategy for Down syndrome, the researchers acknowledged some limitations. These include the exclusion of non-medical and indirect costs from the cost analysis and the lack of comparison with combined first-trimester serum screening and nuchal translucency ultrasound. “It is important to note that the current costs only include direct medical expenses, excluding factors such as human resource costs. Future studies are expected to show higher overall expenses once these additional costs are incorporated,” the researchers wrote.
Despite these limitations, the study provides new and more robust evidence of the utility and cost-effectiveness of NIPT that could influence clinical guidelines and healthcare policy. Current Chinese guidelines recommend NIPT only for women with identified risk factors such as advanced maternal age or a family history of chromosomal abnormalities. Guidelines for its use vary by country around that world. The authors suggest this approach may miss a significant number of DS cases that could otherwise be detected through universal screening. In the U.S., the American College of Obstetricians and Gynecologists (ACOG) recommends that all pregnant individuals be offered prenatal genetic screening and diagnostic testing options, regardless of maternal age or risk of chromosomal abnormalities.
“NIPT should be considered a first-tier screening method for DS,” the researchers wrote. IN this research, universal NIPT screening detected 35 more Down syndrome cases than combining STSS combined with NIPT and provided the most favorable screening outcomes, although not the lowest cost-effectiveness ratio at the current price.
Next steps for the researchers include expanding the analysis to include indirect costs and evaluating additional combinations of first-trimester screening methods. Although the study focused solely on trisomy 21, the higher sensitivity and specificity metrics suggest NIPT could also more accurately detect other chromosomal anomalies compared to STSS, though this was not directly evaluated in the current research.


